Tag Archives: Immune checkpoint therapy

03Aug/18

Cancer Dis: Scientists Reveal New Mechanisms of Drug Resistance in Cancer Immunotherapy

August 3, 2018News, Therapeutic Antibody R&Dimmnunocheckpoint, Immune checkpoint therapy, monoclonal antibody drug, PD-1, pd-L1, therapeutic antibodybiorab

It is well known that the immune system can recognize and remove cancerous cells under normal conditions, but tumor cells will inhibit the immune system in the tumor development process, through differentRead More…

29Jun/18

Scientists Found Key Factors Determining Anticancer Efficacy of Immune Checkpoint Therapy

June 29, 2018News, Therapeutic Antibody R&DFLT3LG, Immune checkpoint therapy, key factors, natural killer NK cell, PD-1, stimulating dendritic cellbiorab

Intratumoral stimulating dendritic cells (SDCs) play a key role in stimulating cytotoxic T lymphocytes and promoting immune responses against cancer. The study of mechanisms regulating the enrichment of SDCs in tumor microenvironmentRead More…